ERBB2 and neoplasm: Interestingly, in vitro studies have shown that tumor cells with high expression of HER2 had an effective transport of the receptor back to the cell surface compared to cells with low HER2 expression, and one could speculate that this phenomenon might impact trastuzumab efficacy in tumors expressing the highest levels of HER2 [70].